Why the study?
Based on evidence of reciprocal regulation between inflammation and calcium unbalance, the authors sought to describe the involvement of the calcium sensor CaMKII in cardiac diseases with an inflammatory drift.
CaMKII may represent a key therapeutic target to modulate the severity of inflammatory-driven degeneration in cardiac diseases.
Answers are grounded in this paper and cite their sources.
CaMKII inhibition merits exploration in inflammatory cardiac disease; leaves open clinical translation pending trials.
Inflammation is a physiological process by which the body responds to external insults and stress conditions, and it is characterized by the production of pro-inflammatory mediators such as cytokines. The acute inflammatory response is solved by removing the threat. Conversely, a chronic inflammatory state is established due to a prolonged inflammatory response and may lead to tissue damage. Based on the evidence of a reciprocal regulation between inflammation process and calcium unbalance, here we described the involvement of a calcium sensor in cardiac diseases with inflammatory drift. Indeed, the Ca²⁺/calmodulin-dependent protein kinase II (CaMKII) is activated in several diseases with an inflammatory component, such as myocardial infarction, ischemia/reperfusion injury, pressure overload/hypertrophy, and arrhythmic syndromes, in which it actively regulates pro-inflammatory signaling, among which includes nuclear factor kappa-B (NF-κB), thus contributing to pathological cardiac remodeling. Thus, CaMKII may represent a key target to modulate the severity of the inflammatory-driven degeneration.
No takes yet. Share an insight, caveat, or question.
Rusciano et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: